{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancers&page=58", "query": { "condition": "Non-small Cell Lung Cancers", "page": 58 }, "page_size": 10 }, "pagination": { "page": 58, "page_size": 10, "total_count": 3680, "total_pages": 368, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancers&page=59&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancers&page=57&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T19:47:36.127Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02511184", "title": "Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK-positive Advanced NSCLC" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2015-10", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-07-01", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511184" }, { "nct_id": "NCT01232452", "title": "A Study in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cixutumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2011-04", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 5, "location_summary": "Chicago, Illinois • Hackensack, New Jersey • Portland, Oregon + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232452" }, { "nct_id": "NCT00768755", "title": "Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "axitinib", "type": "DRUG" }, { "name": "chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2009-01", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Atlanta, Georgia • Decatur, Georgia + 8 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768755" }, { "nct_id": "NCT06497556", "title": "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "KRAS G12C Lung Cancer" ], "interventions": [ { "name": "Divarasib", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2024-09-23", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06497556" }, { "nct_id": "NCT04300556", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Farletuzumab ecteribulin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-08-06", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 24, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300556" }, { "nct_id": "NCT05265429", "title": "Biology of Young Lung Cancer Study: The YOUNG LUNG Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer", "Small Cell Lung Carcinoma", "NUT Carcinoma" ], "interventions": [ { "name": "Data and Specimen Collection", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 500, "start_date": "2023-01-01", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05265429" }, { "nct_id": "NCT07388524", "title": "Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Atezolizumab and Recombinant Human Hyaluronidase", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 336, "start_date": "2027-03-02", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 110, "location_summary": "Beverly Hills, California • Los Angeles, California • Tarzana, California + 92 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Millville", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT07388524" }, { "nct_id": "NCT00043823", "title": "Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Tarceva", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2002-08-01", "completion_date": "2006-05-15", "has_results": false, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043823" }, { "nct_id": "NCT04699123", "title": "The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-small Cell Lung Cancer" ], "interventions": [ { "name": "NC318 800 mg", "type": "DRUG" }, { "name": "NC318 400 mg", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2021-02-04", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699123" }, { "nct_id": "NCT03408561", "title": "Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma", "Colon Carcinoma", "Kidney Carcinoma", "Lymphoma", "Non-Small Cell Lung Carcinoma", "Prostate Carcinoma" ], "interventions": [ { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2017-11-08", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-27T19:47:36.127Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03408561" } ] }